Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy
Open Access
- 1 January 2012
- journal article
- research article
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 27 (2) , 81-4
Abstract
Introduction: Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients. Materials and Methods: Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol. Results: BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the 153 positive cases, 108 (70%) had serum PSA > 100 ng/ml, 42 (28%) had PSA of 20-100 ng/ml and only 3 (2%) had PSA < 20 ng/ml. All the patients with PSA > 100 ng/ml had multiple skeletal metastasis. Of the 117 negative cases, 110 (94%) had a PSA < 20 ng/ml, 5 had between 20 and 100 ng/ml and only 2 (1.8%) had PSA > 100 ng/ml. Of the 113 patients with serum PSA < 20 ng/ml, 110 (97.4%) did not show any bony metastasis. 150/157 (95.5%) patients with PSA > 20 ng/ml had bone metastasis. Using this criterion, 110 (40.7%) scans would have been omitted. Conclusions: Serum PSA < 20 ng/ml have high predictive value in ruling out skeletal metastasis. Our data are in corroboration with results from previous studies that BS should be performed only if PSA > 20 ng/ml. Using this cut-off, unnecessary investigation can be avoided. Avoiding BS in this group of patients would translate into a significant cost-saving and reduction in their psychological and physical burden.Keywords
This publication has 22 references indexed in Scilit:
- EAU Guidelines on Prostate CancerEuropean Urology, 2008
- Prostate cancer epidemiologyFrontiers in Bioscience-Landmark, 2006
- Prostate‐specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in JapanInternational Journal of Urology, 2005
- Prostate carcinoma presentation, diagnosis, and stagingCancer, 2003
- Screening for prostate cancer: evidence and perspectivesBJU International, 2001
- Predictive Value of Prostate-specific Antigen, Tumour Stage and Tumour Grade for the Outcome of Bone Scintigraphy in Patients with Newly Diagnosed Prostate CancerScandinavian Journal of Urology and Nephrology, 1999
- Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancerUrology, 1996
- The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- Prognostic Value of Raised Prostatic Acid Phosphatase and Negative Skeletal Scintigraphy in Prostatic CancerBritish Journal of Urology, 1991
- The Role of Bone Scanning in the Assessment of Prostatic CarcinomaBritish Journal of Urology, 1978